Gilead Records Positive Phase III Results In HIV
GILDGilead(GILD) Seeking Alpha·2024-06-22 15:56

Gilead Sciences, Foster City, CA Tomsmith585/iStock Unreleased via Getty ImagesGilead Sciences (NASDAQ:GILD) on Thursday announced positive topline results from an interim analysis of its Phase III PURPOSE 1 trial. The trial which tested the efficacy of twice-yearly lenacapavir versus once daily Truvada and Descovy in approximately 5,300 women at risk of contracting HIV in South Africa and Uganda, found 0 incident cases of HIV infection in the lenacapavir group. In other words, among the 2,124 treated wit ...